SCHEMBL20819192

SCHEMBL20819192

CCOC(=O)CC(=O)CSc1nnc(C)s1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 8/20 0.58
▸ GAA P10253 4/20 0.58
▸ HPGD P15428 3/20 0.58
▸ L3MBTL1 Q9Y468 1/20 0.58
▸ SMN1; SMN2 Q16637 3/20 0.52
▸ LMNA P02545 2/20 0.52
▸ NPSR1 Q6W5P4 2/20 0.52
▸ TSHR P16473 2/20 0.52
▸ USP2 O75604 1/20 0.52
▸ PKM P14618 1/20 0.52
▸ HTT P42858 2/20 0.50
▸ POLB P06746 1/20 0.50
▸ NPC1 O15118 1/20 0.49
▸ RAB9A P51151 1/20 0.49
▸ HSD11B1 P28845 4/20 0.48
▸ KMT2A Q03164 2/20 0.47
▸ MAPT P10636 2/20 0.47
▸ MEN1 O00255 1/20 0.47
▸ CYP1A2 P05177 1/20 0.47
▸ CYP2D6 P10635 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4676031 0.79 GAA (0.61) ALDH1A1GAAHPGDL3MBTL1SMN1; SMN2
SCHEMBL11795775 0.76 GAA (0.67) ALDH1A1GAAHPGDL3MBTL1LMNA
SCHEMBL20819243 0.75 GAA (0.56) ALDH1A1GAAHPGDL3MBTL1SMN1; SMN2
SCHEMBL6251239 0.74 RAB9A (0.64) ALDH1A1GAAHPGDSMN1; SMN2LMNA
SCHEMBL11927276 0.74 GAA (0.73) ALDH1A1GAAHPGDL3MBTL1SMN1; SMN2
SCHEMBL1686848 0.74 GAA (1.00) ALDH1A1GAAHPGDL3MBTL1LMNA
SCHEMBL10402042 0.74 GAA (0.73) ALDH1A1GAAHPGDL3MBTL1LMNA
SCHEMBL8957661 0.73 ALDH1A1 (0.68) ALDH1A1GAAHPGDL3MBTL1SMN1; SMN2
SCHEMBL999575 0.73 ALDH1A1 (1.00) ALDH1A1GAAHPGDL3MBTL1SMN1; SMN2
SCHEMBL8957668 0.73 ALDH1A1 (0.68) ALDH1A1GAAHPGDL3MBTL1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200308165-A1 Compounds as Ras Inhibitors and Use Thereof D. E. SHAW RESEARCH, LLC 2020-10-01 — — US disclosed
US-20200308165-A1 Compounds as Ras Inhibitors and Use Thereof D. E. SHAW RESEARCH, LLC 2020-10-01 — — US disclosed
EP-3681499-A1 COMPOUNDS AS RAS INHIBITORS AND USE THEREOF D.E. Shaw Research, LLC (US) 2020-07-22 — — EP disclosed
WO-2019055540-A1 COMPOUNDS AS RAS INHIBITORS AND USE THEREOF D.E. SHAW RESEARCH, LLC (US) 2019-03-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200308165-A1 Compounds as Ras Inhibitors and Use Thereof KRAS, NRAS, HRAS ALDH1A1 2215/4885GAA 598/4885HPGD 2319/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback